CB-03-01 Investor update
Collapse
X
-
The reason they don't test anti-androgens first for AA and instead for things like acne is because of potential markets.
Would a teenager be willing to use a new treatment for acne if they know it is being used to make bald men hairy?
But if a drug corners the acne market first and then the company can bring out that same drug for AA without reducing their potential market.Comment
-
yup. hair trials take much longer. And the market for acne actually is bigger whether you can believe it or not. Pretty much everyone gets acne. Has nothing to do with what the other dude above said at all. The lady from Hygeia laid it out pretty succinctly earlier. It's just crazy that all of this hasn't already happened, these topical anti androgens have been known forever. Propecia is the worst thing to have ever happened to hairloss research.Comment
-
yup. hair trials take much longer. And the market for acne actually is bigger whether you can believe it or not. Pretty much everyone gets acne. Has nothing to do with what the other dude above said at all. The lady from Hygeia laid it out pretty succinctly earlier. It's just crazy that all of this hasn't already happened, these topical anti androgens have been known forever. Propecia is the worst thing to have ever happened to hairloss research.Comment
-
Not much to say, they expect to finish Phase 3 for acne with CB-03-01 by the end of 2017. And it shows great promise without serious side effects. The vehicle is BID 1% (don't know what this is).
For alopecia they are taking NW2 - NW5s, mostly NW3 and NW3 vertex to see the results of CB vs. placebo and minox. Phase 2 should finish by the end of this year.
So they are applying 1% CB twice a day.
Re: CB's strength, it doesn't really matter that CB is a slightly weaker AA than others. That just means you may need a higher concentration. The important thing is what happens when it penetrates the skin ie it supposedly quickly degrades to an inactive form. Unlike say flutamide which is a very strong AA but has systemic effects.
I don't recall Cosmo ever saying CB causes massive new hair growth. The pilot study showed an increase in hair count but that doesn't mean new hairs, it just means more hairs in anagen, which means more hairs at any given time. It won't cause much new growth anyway. AAs do not grow new hair. They don't even really reverse miniaturisation except in very early or very rare cases. It should significantly outperform Propecia though, because Propecia only lowers scalp DHT by about 30%. CB should beat that comfortably, and block T as well as DHT.
The best way to think of CB is basically the same as RU but more stable. And also quality control assured of it gets released officially.Comment
-
BID 1% is not the vehicle. BID means bis in diem which is Latin for twice a day. It's standard pharma terminology.
So they are applying 1% CB twice a day.
Re: CB's strength, it doesn't really matter that CB is a slightly weaker AA than others. That just means you may need a higher concentration. The important thing is what happens when it penetrates the skin ie it supposedly quickly degrades to an inactive form. Unlike say flutamide which is a very strong AA but has systemic effects.
I don't recall Cosmo ever saying CB causes massive new hair growth. The pilot study showed an increase in hair count but that doesn't mean new hairs, it just means more hairs in anagen, which means more hairs at any given time. It won't cause much new growth anyway. AAs do not grow new hair. They don't even really reverse miniaturisation except in very early or very rare cases. It should significantly outperform Propecia though, because Propecia only lowers scalp DHT by about 30%. CB should beat that comfortably, and block T as well as DHT.
The best way to think of CB is basically the same as RU but more stable. And also quality control assured of it gets released officially.Comment
-
I don't think there's any point to CB. The PGD2 blockers will be more useful for maintenance, and things like SM or BIM seem much more promising re-growth wise. I doubt the side effect profile for CB is too bad, but I also don't think it'll be all that useful.Comment
-
Maybe but your basically guessing. I dont think any of the past small studies they have done nor people buying chemicals from unlicensed manufacturers and experimenting on their own is actually a good representation of the effectiveness of the actual final product or chemical. The better safety profile is one of the biggest advantages to it even if its no better than fin.Comment
-
Maybe but your basically guessing. I dont think any of the past small studies they have done nor people buying chemicals from unlicensed manufacturers and experimenting on their own is actually a good representation of the effectiveness of the actual final product or chemical. The better safety profile is one of the biggest advantages to it even if its no better than fin.Comment
-
CB will probably get shelved. Salix, who are running the trials in the US, was just bought out by Valeant. Valeant has a long history of buying up companies and shelving the drugs they have in development.
Comment
-
CB will probably get shelved. Salix, who are running the trials in the US, was just bought out by Valeant. Valeant has a long history of buying up companies and shelving the drugs they have in development.
http://www.reuters.com/article/2015/...0LQ0V420150223Comment
-
CB will probably get shelved. Salix, who are running the trials in the US, was just bought out by Valeant. Valeant has a long history of buying up companies and shelving the drugs they have in development.
http://www.reuters.com/article/2015/...0LQ0V420150223Comment
-
Not sure if I buy that - if Cosmo have contracted Salix to run the trials, this will be run out of different dept to drug development...clinical trials as a managed service are a nice income earner for any drug company - you dont bin those... fair margins and good revenue
Intrepid Therapeutics is running the USA trial.
Still, for us i think good news Cosmo didnt merge with Salix few months ago.Comment
-
Comment
Comment